NCT05610878 Efficacy of Preconditioned Adipose-Derived Stem Cells in Fat Grafting
| NCT ID | NCT05610878 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of the Punjab |
| Condition | Romberg Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2020-11-20 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2020-11-20 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the comparison of therapeutic potential of curcumin preconditioned adipose derived stem cells (ASCs) enrichment fat grafting, naïve ASCs enrichment fat grafting and conventional fat grafting to correct facial contour deformities that cause aesthetic complications in patients.
Eligibility Criteria
Inclusion criteria * Age 18-50 years (male or female) * Body-mass index 20-30 kg/m² * Suitable for liposuction as assessed by the expected cosmetic results * Provided signed informed consent Exclusion criteria * Systemic disorders include autoimmune diseases, hemorrhagic diseases, bone marrow aplasia, sepsis, cancer, and others * Local disorders include acne, infections and others * Risk factors include smoking, uncompensated diabetes, hypertension, and allergy to the drugs used for general anesthesia * Microbiological contamination of either the cell culture or the transplanted tissue
Contact & Investigator
Azra Mehmood, PhD
PRINCIPAL INVESTIGATOR
Center of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore
Frequently Asked Questions
Who can join the NCT05610878 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Romberg Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05610878 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05610878 currently recruiting?
Yes, NCT05610878 is actively recruiting participants. Contact the research team at azra_mehmood@hotmail.com for enrollment information.
Where is the NCT05610878 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT05610878 clinical trial?
NCT05610878 is sponsored by University of the Punjab. The principal investigator is Azra Mehmood, PhD at Center of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore. The trial plans to enroll 24 participants.